Corvus Pharmaceuticals, Inc.CRVSNASDAQ
LOADING
|||
R&D Expense Growth Recovery in Progress
Trending higher, below historical average, structural decline.
Left:
||||
Year-over-year research & development expense growth
Latest
17.30%
↓ 99% below average
Average (9y)
2742.62%
Historical baseline
Range
High:27283.91%
Low:-32.46%
CAGR
-55.9%
Structural decline
| Period | Value |
|---|---|
| 2024 | 17.30% |
| 2023 | -32.46% |
| 2022 | -15.96% |
| 2021 | -8.53% |
| 2020 | -16.18% |
| 2019 | -1.58% |
| 2018 | -16.67% |
| 2017 | 57.74% |
| 2016 | 158.60% |
| 2015 | 27283.91% |